COLUMBUS, Ohio--Women who said they used an NSAID (usually aspirin or ibuprofen) regularly for 5 years or more had a 40% lower risk of breast cancer than those who did not report such use, Dr. Randall E. Harris and his colleagues at the Ohio State University Comprehensive Cancer Center have found.
COLUMBUS, Ohio--Women who said they used an NSAID (usually aspirinor ibuprofen) regularly for 5 years or more had a 40% lower riskof breast cancer than those who did not report such use, Dr. RandallE. Harris and his colleagues at the Ohio State University ComprehensiveCancer Center have found.
This case-control study involved 303 breast cancer patients diagnosedat the University's Arthur G. James Cancer Hospital and 906 controls(women who underwent screening mam-mography and had no detectablebreast disease). Risk factor data were collected by personal interviewsat the time of diagnosis or screening.
Significantly more women in the control group (27%) reported regularNSAID use than did the breast cancer patients (19%). Calculationof odds ratios showed a reduction in risk of 36% for those whotook NSAIDs three or more times a week for 6 months or more, anda reduction of 40% among those who used NSAIDs seven times a weekfor 5 years or more.
These results, published in Oncology Reports (2:591-592, 1995),are supported by an earlier study by Dr. Harris' team that matched744 newly diagnosed breast cancer patients with 767 controls drawnfrom hospital patients with medical conditions unrelated to breastcancer.
That study found a 37% reduction in breast cancer risk among womenwho reported using NSAIDs at least three times a week for at least5 years (Prev Med 24:119-120, 1995).
Ribociclib Combo Yields iDFS Improvement in HR+/HER2– Breast Cancer
December 9th 2023Combining ribociclib with nonsteroidal aromatase inhibitor treatment also produces relapse-free survival and distant disease-free survival benefits in patients with HR-positive, HER2-negative early-stage breast cancer.
Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer
October 30th 2023Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.
Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment
May 8th 2023Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.